摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(2-pyridyl)[5H]pyrrolo[2,3-b]pyrazine

中文名称
——
中文别名
——
英文名称
6-(2-pyridyl)[5H]pyrrolo[2,3-b]pyrazine
英文别名
6-(pyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazine;2-{5H-pyrrolo[2,3-b]pyrazin-6-yl}pyridine;6-pyridin-2-yl-5H-pyrrolo[2,3-b]pyrazine
6-(2-pyridyl)[5H]pyrrolo[2,3-b]pyrazine化学式
CAS
——
化学式
C11H8N4
mdl
——
分子量
196.211
InChiKey
IXQOVNQMUSNLCC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    54.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    2-乙炔基吡啶N-(3-chloropyrazin-2-yl)-methanesulfonamide(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride sodium carbonate 、 lithium chloride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.0h, 以46%的产率得到6-(2-pyridyl)[5H]pyrrolo[2,3-b]pyrazine
    参考文献:
    名称:
    N-(3-氯吡嗪-2-基)-甲磺酰胺和炔烃的钯催化杂环化反应生成6-取代的5 H-吡咯并[2,3- b ]吡嗪
    摘要:
    我们在本文中报道了6-取代的-5 H-吡咯并[2,3- b ]吡嗪的有效和方便的合成。该反应是钯催化的杂环化过程,然后脱保护以得到所需的吡咯并[2,3- b ]吡嗪底物。该反应从容易获得的N-(3-氯吡嗪-2-基)-甲磺酰胺和可商购的末端炔烃开始,并与芳基和烷基炔烃一起使用。
    DOI:
    10.1016/j.tetlet.2004.08.155
点击查看最新优质反应信息

文献信息

  • Azaindoles
    申请人:——
    公开号:US20040009983A1
    公开(公告)日:2004-01-15
    The invention is directed to compositions containing physiologically active compounds of general formula (I): 1 wherein R 1 is aryl or heteroaryl; R 2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, —Z 1 R 8 , —C(═O)—NY 3 Y 4 , —CO 2 R 8 , —NY 3 Y 4 , —N(R 6 )—C(═O)—R 7 , —N(R 6 )—C(═O)—NY 3 Y 4 , —N(R 6 )—C(═O)—OR 7 , —N(R 6 )—SO 2 —R 7 , —N(R 6 )—SO 2 —NY 3 Y 4 and one or more halogen a toms ; R 3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, —C(═O)—OR 5 or —C(═O)—NY 3 Y; and X 1 represents N, CH, C-halo, C—CN, C—R 7 , C—NY 3 Y 4 , C—OH, C—Z 2 R 7 , C—C(═O)—OR 5 , C—C(═O)—NY 3 Y 4 , C—N(R 8 )—C(═O)—R 7 , C—SO 2 —NY 3 Y 4 , C—N(R 8 )—SO 2 —R 7 , C-alkenyl, C-alkynyl or C—NO 2 ; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.
    这项发明涉及含有一般式(I)中生理活性化合物的组合物:其中R1为芳基或杂芳基;R2代表氢、酰基、氰基、卤素、可选择地由氰基、杂芳基、杂环烷基、—Z1R8、—C(═O)—NY3Y4、—CO2R8、—NY3Y4、—N(R6)—C(═O)—R7、—N(R6)—C(═O)—NY3Y4、—N(R6)—C(═O)—OR7、—N(R6)—SO2—R7、—N(R6)—SO2—NY3Y4和一个或多个卤原子取代的较低烯基或较低烷基;R3代表氢、芳基、氰基、卤素、杂芳基、较低烷基、—C(═O)—OR5或—C(═O)—NY3Y;X1代表N、CH、C-卤素、C—CN、C—R7、C—NY3Y4、C—OH、C—Z2R7、C—C(═O)—OR5、C—C(═O)—NY3Y4、C—N(R8)—C(═O)—R7、C—SO2—NY3Y4、C—N(R8)—SO2—R7、C-烯基、C-炔基或C—NO2;以及它们的前药、这些化合物及其前药的药学上可接受的盐和溶剂,以及在一般式(I)范围内的新化合物。这些化合物和组合物具有有价值的药物特性,特别是抑制蛋白激酶的能力。
  • Pyrrolopyrazines as kinase inhibitors
    申请人:CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    公开号:EP1388541A1
    公开(公告)日:2004-02-11
    The invention relates to pyrrolo [2,3b]-pyrazine derivatives having the general formula (I) :    wherein : R2 and R3 are identical or different and represent H, C1-C6 alkyl, said alkyl being a straight or branched-chain alkyl, which can be substituted, R6 is an optionally substituted aromatic cycle Ar or a cycloalkyl, said cycloalkyl being optionally substituted by an aryl group which can also be substituted, R7 is H, C1-C6 alkyl, (alk.)n-hal., CH2-CH = CH2, CH2-cycloalkyl, CH2-Ar, with "alk." being a C1-C6 alkylene group, n being 1-6, Z is H or CH3. Application as active principle of pharmaceutical compositions, particularly for treating or preventing neurodegenerative disorders and proliferative disorders.
    该发明涉及具有一般式(I)的吡咯并[2,3b]-吡嗪衍生物:   其中:R2和R3相同或不同,代表H,C1-C6烷基,所述烷基为直链或支链烷基,可以被取代,R6是可选择被取代的芳香环Ar或环烷基,所述环烷基可被芳基取代,R7是H,C1-C6烷基,(烷基)n-卤,CH2-CH = CH2,CH2-环烷基,CH2-Ar,其中"烷基"是C1-C6烷基,n为1-6,Z为H或CH3。用作药物组合物的活性成分,特别用于治疗或预防神经退行性疾病和增殖性疾病。
  • [EN] AZAINDOLES<br/>[FR] AZAINDOLES
    申请人:AVENTIS PHARMA LTD
    公开号:WO2003000688A1
    公开(公告)日:2003-01-03
    The invention is directed to physiologically active compounds of general formula (I): and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    该发明涉及具有通式(I)的生理活性化合物及含有这种化合物的组合物,以及这种化合物和它们的前药,以及这种化合物和它们的前药的药学上可接受的盐和溶剂化合物,以及在公式(I)范围内的新化合物。这些化合物和组合物具有有价值的药物特性,特别是抑制激酶的能力。
  • Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects
    作者:Yvette Mettey、Marie Gompel、Virginie Thomas、Matthieu Garnier、Maryse Leost、Irène Ceballos-Picot、Martin Noble、Jane Endicott、Jean-michel Vierfond、Laurent Meijer
    DOI:10.1021/jm020319p
    日期:2003.1.1
    Cyclin-dependent kinases (CDKs) regulate the cell cycle, apoptosis, neuronal functions, transcription, and exocytosis. The observation of CDK deregulations in various pathological situations suggests that CDK inhibitors may have a therapeutic value. In this article, we report on the identification of 6-phenyl[5H]pyrrolo[2,3-b]pyrazines (aloisines) as a novel potent CDK inhibitory scaffold. A selectivity study performed on 26 kinases shows that aloisine A is highly selective for CDK1/cyclin B, CDK2/cyclin A-E, CDK5/p25, and GSK-3alpha/beta; the two latter enzymes have been implicated in Alzheimer's disease. Kinetic studies, as well as the resolution of a CDK2-aloisine cocrystal structure, demonstrate that aloisines act by competitive inhibition of ATP binding to the catalytic subunit of the kinase. As observed with all inhibitors reported so far, aloisine interacts with the ATP-binding pocket through two hydrogen bonds with backbone nitrogen and oxygen atoms of Leu 83. Aloisine inhibits cell proliferation by arresting cells in both G1 and G2.
  • AZAINDOLES
    申请人:Aventis Pharma Limited
    公开号:EP1263759B1
    公开(公告)日:2010-09-08
查看更多

同类化合物

舒立克隆 吡唑并[1,5-a]吡咯并[2,1-C]吡嗪 吡咯并[1,2-a]噻吩并[2,3-e]吡嗪 吡咯并[1,2-a]吡嗪-8-甲醛 吡咯并[1,2-a]吡嗪-6-甲醛(9CI) 吡咯并[1,2-a]吡嗪-3-羧酸乙酯 吡咯并[1,2-a]吡嗪-3-羧酸 吡咯并[1,2-a]吡嗪 吡咯并[1,2-A]吡嗪-6-甲醇 右佐匹克隆 佐匹克隆氧化物 佐匹克隆杂质3 佐匹克隆 二羰雙吡咯 乙酰氨基-6-吡咯并[1,2-a]噻吩并[2,3-e]吡嗪 乌帕替尼 N-甲基-5-溴-4,7-二氮杂吲哚 N-去甲基佐匹克隆 7-碘-5H-吡咯并[2,3-b]吡嗪 7-甲基-6,8-二(甲硫基)吡咯并[1,2-a]吡嗪 7-氯甲基氧基-羰基氧基-6-(5-氯吡啶-2-基)-6,7-二氢-5H-吡咯并[3,4-b]吡嗪-5-酮 6-甲基-吡咯并[1,2-a]吡嗪 6-溴吡咯[1,2-A]吡嗪-3-羧酸乙酯 6-(7-氯-1,8-萘啶-2-基)-6,7-二氢-7-羟基-5H-吡咯并[3,4-b]吡嗪-5-酮 6-(7-氯-1,8-萘啶-2-基)-2,3,6,7-四氢-7-羟基-5H-1,4-二噻英并[2,3-c]吡咯-5-酮 6-(5-氯-吡啶-2-基)-7-苯氧基羰基氧基-6,7-二氢-吡咯并3,4-b吡嗪-5-酮 6-(5-氯-2-吡啶基)-6,7-二氢-7-羟基-5H-吡咯并[3,4-b]吡嗪-5-酮 6-(5-氯-1,8-萘啶-2-基)-2,3,6,7-四氢-7-氧代-5H-1,4-二噻英并[2,3-c]吡咯-5-基4-甲基哌嗪-1-羧酸酯 6,7,8,9-四氢吡嗪并[1,2-A]吲哚-1(2H)-酮 5H-吡嗪并[2,3-b]吲哚 5H-吡咯并[2,3-b]吡嗪-7-羧醛 5H-吡咯并[2,3-b]吡嗪-2-羧酸甲酯 5H-吡咯[2,3-B]吡嗪-7-乙酸 5-溴-4,7-二氮杂吲哚 5-氯-2-(7-氯-1,8-萘啶-2-基)-3-羟基异吲哚啉-1-酮 5-氢吡咯并[2,3-b]吡嗪-7-甲酸 4,7-二氮杂吲哚 3-羟基-2-(7-甲氧基-[1,8]萘啶-2-基)-2,3-二氢-异吲哚-1-酮 3-甲基吡咯并[1,2-a]吡嗪-1(2H)-酮 3-溴-5H-吡咯并[2,3-b]吡嗪 3-溴-4,7-二氮杂吲哚 3-氯-5H-吡咯并[2,3-b]吡嗪 3,6,7-三甲基吡咯并[1,2-a]吡嗪 2-溴-7-碘-5H-吡咯并[2,3-B]吡嗪 2-溴-7-硝基-5H-吡咯并[2,3-B]吡嗪 2-溴-6-甲基-5H-吡咯并[2,3-b]吡嗪-7-羧酸乙酯 2-溴-6-甲基-5H-吡咯并[2,3-B]吡嗪-7-羧酸甲酯 2-溴-5H-吡咯并[2,3-b]吡嗪-7-羧酸甲酯 2-溴-5H-吡咯并[2,3-b]吡嗪-7-羧酸 2-溴-5H-吡咯并[2,3-B]吡嗪-7-胺